Bevacizumab + Capecitabine + Pembrolizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microsatellite Stable
Conditions
Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Trial Timeline
Apr 18, 2018 → Jan 30, 2024
NCT ID
NCT03396926About Bevacizumab + Capecitabine + Pembrolizumab
Bevacizumab + Capecitabine + Pembrolizumab is a phase 2 stage product being developed by Merck for Microsatellite Stable. The current trial status is completed. This product is registered under clinical trial identifier NCT03396926. Target conditions include Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03396926 | Phase 2 | Completed |
Competing Products
11 competing products in Microsatellite Stable
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| Balstilimab + Botensilimab | Agenus | Phase 2 | 44 |